Angiogenesis pp 475-492 | Cite as

Clinical Trials of Angiogenesis-Based Therapies: Overview and New Guiding Principles

  • William W. Li
  • Vincent W. Li
  • Richard Casey
  • Dimitris Tsakayannis
  • Erwin A. Kruger
  • Andrew Lee
  • Yee-Li Sun
  • Christopher A. Bonar
  • Shawna Cornelius
Part of the NATO ASI Series book series (NSSA, volume 298)


Angiogenesis, new blood vessel growth, is a “common denominator” pathologic feature in many serious diseases, including cancer, coronary artery disease, stroke, blindness, arthritis, and more than one dozen other major conditions. Against the backdrop of largely unsatisfactory current treatments for these conditions, a new form of medical therapy aimed at controlling angiogenesis is emerging after three decades of basic scientific research. In simplest terms, angiogenesis modulating drugs restore growth control over the vascular system — by either turning “on” or turning “off” angiogenesis. A number of angiogenesis-modulating compounds, both stimulators and inhibitors, are currently in clinical trials in the United States, Canada and Europe. The reality of these trials, and some exciting early positive results, heralds an exciting era of medical therapy for the new millennium, and offers renewed hope for patients suffering from currently incurable diseases such as cancer.


Diabetic Retinopathy Maximal Tolerate Dose Antiangiogenic Therapy Antiangiogenic Agent Infantile Hemangioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adamis A., Shima D., Tolentino M., Gragoudas E., Ferrara N., Folkman J., D’Amore P., Miller J. Inhibition of VEGF prevents ocular neovascularization in a non-human primate. Archives of Ophthalmology 196; 114:66–71.Google Scholar
  2. 2.
    Asahara, T., Murohara, T., Sullivan, A., Isner J. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964–67PubMedCrossRefGoogle Scholar
  3. 3.
    Ausprunk, D., Folkman, J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977; 14:53–65PubMedCrossRefGoogle Scholar
  4. 4.
    Breier, G., Damert, A., Plate, K.H., Risau, W. Angiogenesis in embryos and ischemic diseases. Thrombosis Haemostasis 1997; 78:679–83Google Scholar
  5. 5.
    Burr L.P.H. Intussusceptive microvascular growth: a new mechanism of capillary network formation in angiogenesis. In: R Steiner, PB Weiss, R Langer. Angiogenesis: key principles of science, technology and medicine. Basel: Birkhauser Verlag, 1992; 393–400Google Scholar
  6. 6.
    Casey, R. and Li W. Factors controlling ocular angiogenesis. American Journal of Ophthalmology 1997; 124(4): 521–529.PubMedGoogle Scholar
  7. 7.
    Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., Ryan, T.E., Bruno, J., Radziejewski, C., Maisonpierre, P.C., Yancopoulos, G.D. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161–69.PubMedCrossRefGoogle Scholar
  8. 8.
    Engler, C.B., Sander, B., Koefoed, P., Larsen, M., Vinding, T., and Lund-Anderson, H. Interferon alpha-2a treatment of patients with subfoveal neovascular macular degeneration. Acta Ophthalmologica 1993; 71:2731Google Scholar
  9. 9.
    Ezekowitz R.B.A., Mulliken J.B., Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. The New England Journal of Medicine 1992; 326:1456–63PubMedCrossRefGoogle Scholar
  10. 10.
    Folkman J. Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine 1971; 285:1182–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995; 1:27–31PubMedCrossRefGoogle Scholar
  12. 12.
    Folkman J. New perspectives in clinical oncology from angiogenesis research. European Journal of Cancer 1996; 32A:2534–39CrossRefGoogle Scholar
  13. 13.
    Folkman J. Antiangiogenic therapy, in: Cancer: Principles & Practice of Oncology, Fifth Edition, ed. VT DeVita Jr., S Hellman, SA Rosenberg. Lippincott-Raven Publishers, Philadelphia, 1997: 3075–85.Google Scholar
  14. 14.
    Folkman J., Szabo S., Stovroff M., McNeil P., Li W., Shing Y. Duodenal ulcer: discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Annals of Surgery 1991; 214:414–27.PubMedCrossRefGoogle Scholar
  15. 15.
    Fung, W.E. Interferon alpha 2a treatment for age-related macular degeneration. American Journal of Ophthalmology 1991; 112:349–350.PubMedGoogle Scholar
  16. 16.
    Gill P.S., Lunardi-Iskandar, Y., Louie, S., Tulpule, A., Zheng, T., Espina, B.M., Besnier, J.M., Hermans, P., Levine, A.M., Bryant, J.L., and Gallo, R.C. The effects of preparation of human chorionic gonadotropin on AIDS-related Kaposi’s sarcoma. The New England Journal of Medicine 1996; 335: 1261–69.PubMedCrossRefGoogle Scholar
  17. 17.
    Guyer, D.R., Tiedeman, J., Yannuzzi, L.A., Slakter, J.J., Parker, D., Kelley, J., Tang, R.A., Marmor, M., Abrams, G., Miller, J.W., Gragoudas, E.R. Interferon-associated retinopathy. Archives of Ophthalmology 1993; 111:350–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Harada, K., Grossman, W., Friedman, M., Edelman, E.R., Prasad, P.V., Keighley, C.S., Manning, W.J., Sellke, F.W., Simons, M. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. Journal of Clinical Investigation 1994; 94:623–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Hertig, A.T. Angiogenesis in the early human chorion and in the primary placenta of the macaque monkey. Contrib Embryol 1935; 25:39–81.Google Scholar
  20. 20.
    Hirschi, K.K., D’Amore, P.A. Pericytes in the microvasculature. Cardiovascular Research 1996; 32:687–98.PubMedGoogle Scholar
  21. 21.
    Holmgren, L., O’Reilly, M.S., Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995; 1:149–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Holmgren, L. Antiangiogenesis restricted tumor dormancy. Cancer and Metastasis Reviews 1996; 15:241–245.PubMedCrossRefGoogle Scholar
  23. 23.
    Isner, J.M, Pieczek, A., Schainfeld, R., Blair, R., Haley, L., Asahara, T., Rosenfield, K., Razvi, S., Walsh, K., Symes, J.F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF(165) in patient with ischaemic limb. The Lancet 1996; 348(9024):370–374.CrossRefGoogle Scholar
  24. 24.
    Jain, R.K. Barriers to drug delivery in solid tumors. Scientific American 1994; 271:58–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Kudelka, A.P., Levy, T., Verschraegen, C.F., Edwards, C.L., Piamsomboon, A., Termrungruanglert, W., Freedman, R.S., Kaplan, A.L., Kieback, D.G., Meyers, C.A., Jaeckle, K.A., Loyer, E., Steger, M., Mante, R., Mavligit, G., Killian, A., Tang, R.A., Gutterman, J.U., and Kavanagh, J.J. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clinical Cancer Research 17; 3:1501–05.Google Scholar
  26. 26.
    Li, V.W., Folkerth, R.D., Watanabe, H., Yu, C., Rupnick, M., Barcus, P., Scott, R.M., Black, P.McL., Sallan, S.R., Folkman, J. Basic fibroblast growth factor in the cerebrospinal fluid of children with brain tumours — correlation with microvessel count in the tumour. Lancet 1994; 344:82–86.PubMedCrossRefGoogle Scholar
  27. 27.
    Li, W.W., Li, V.W., Casey, R. Arterial gene therapy. Lancet 1996; 348: 1381.PubMedCrossRefGoogle Scholar
  28. 28.
    Lopez, J.J. and Simons, M. Local extravascular growth factor delivery in myocardial ischemia. Drug delivery 1996; 3:143–47.CrossRefGoogle Scholar
  29. 29.
    Loughnan, M., Elder, J., Kemp, A. Treatment of a massive orbital-capillary hemangioma with interferon alfa-2b: short-term results. Archives of Ophthalmology 1992; 110:1366–67.PubMedCrossRefGoogle Scholar
  30. 30.
    Lupia, E., Montrucchio, G., Battaglia, E., Modena, V., Camussi, G. Role of tumor necrosis factor alpha and platelet activating factor in neoangiogenesis induced by synovial fluid of patients with rheumatoid arthritis. European J Immunol 1996; 26:1690–94.CrossRefGoogle Scholar
  31. 31.
    Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N., Daly, T.J., Davis, S., Sato, T.N., Yancopoulos, G.D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Miller, J.W. Vascular endothelial growth factor and ocular neovascularization. American Journal of Pathology 1997; 151:13–23.PubMedGoogle Scholar
  33. 33.
    Nyugen, M., Watanabe, H., Budson, A.E., Richie, J.P., Folkman, J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. Journal of the National Cancer Institute 1993; 85:241.CrossRefGoogle Scholar
  34. 34.
    Oliver, S.J., Banquerigo, M.L., Brahn, E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilized, taxol. Cell Immunol 1994; 157:291–99.PubMedCrossRefGoogle Scholar
  35. 35.
    O’Reilly, M.S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W.S., Flynn, E., Birkhead, J.R., Olsen, B.R., Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277–85.PubMedCrossRefGoogle Scholar
  36. 36.
    Pluda, J.M. Tumor-associated angiogenesis: mechanisms, clinical implications and therapeutic strategies. Seminars in Oncology 1997; 24:203–18.PubMedGoogle Scholar
  37. 37.
    Pluda, J.M., Feigal, E., Yarchoan, R. Noncytotoxic approaches to the treatment of HIV-associated Kaposi’s sarcoma. Oncology 1993; 7:25–33.PubMedGoogle Scholar
  38. 38.
    Pu, L-Q, Sniderman, A.D., Brassard, R., Lachapelle, K.J., Graham, A.M., Lisbona, R., and Symes, J.F. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993; 88:208–15PubMedCrossRefGoogle Scholar
  39. 39.
    Relf, M., Lejeune, S., Scott, P.A.E., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R., and Harris, A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Research 1997; 57:963–69.PubMedGoogle Scholar
  40. 40.
    Risau, W. Mechanisms of angiogenesis. Nature 1997: 386: 671–74.PubMedCrossRefGoogle Scholar
  41. 41.
    Robson, M.C. Exogenous growth factor application effect on human wound healing. Progress in Dermatology 1996; 30:1–7] [DL Steed and the Diabetic Ulcer Study Group. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Journal of Vascular Surgery 1995; 21:71–81.Google Scholar
  42. 42.
    Schweigerer, L., and Fotsis, T. Angiogenesis and angiogenesis inhibitors in pediatric diseases. European Journal of Pediatrics 1992; 151:472–76.PubMedCrossRefGoogle Scholar
  43. 43.
    Skowsky, W.R., Siddiqui, T., Hodgetts, D., Lambrou, F.H., Stewart, M.Y., and Foster, M.T. A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effects and ophthalmologic effects. Journal of Diabetes and Its Complications 196; 10:94–99.Google Scholar
  44. 44.
    Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N., Yancopoulos, G.D. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during mebryonic angiogenesis. Cell 1996; 87:1171–80.PubMedCrossRefGoogle Scholar
  45. 45.
    Tolentino, M.J., Miller, J.W., Gragoudas, E.S., Chatzistefanou, K., Ferrara, N., Adamis, A.P. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Archives of Ophthalmology 1996; 114; 964–70.PubMedCrossRefGoogle Scholar
  46. 46.
    Vogt, B. and Frey, F.J. Inhibition of angiogenesis in Kaposi’s sarcoma by Captopril. The Lancet 1997; 349:1149.CrossRefGoogle Scholar
  47. 47.
    White, C.W., Sondheimer, H.M., Crouch, E.C., Wilson, H., Fan, L.L. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. The New England Journal of Medicine 189; 320:1197–200.Google Scholar
  48. 48.
    Yanagisawa-Miwa, A., Uchida, Y., Nakamura, F., Tomaru, T., Kido, H., Kamijo, T., Sugimoto, T., Kaji, K., Utsuyama, M., Kurashima, C., Ito, H. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257:1401–03.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • William W. Li
    • 1
  • Vincent W. Li
    • 1
  • Richard Casey
    • 1
  • Dimitris Tsakayannis
    • 2
  • Erwin A. Kruger
    • 1
  • Andrew Lee
    • 1
  • Yee-Li Sun
    • 1
  • Christopher A. Bonar
    • 1
  • Shawna Cornelius
    • 1
  1. 1.The Angiogenesis FoundationCambridgeUSA
  2. 2.The Angiogenesis Foundation, EuropeAthensGreece

Personalised recommendations